The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 12.52 — safe zoneOK
- Earnings quality 70/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as AGIOS PHARMACEUTICALS, INC. reports it. History and quarterly detail are in the app.
- Product revenue, net$54.0M
Leadership changes
From AGIOS PHARMACEUTICALS, INC.'s own filings, the day they're filed.
- David P. Schenkein · Directors · departureeff. 2025-02-28
- Cynthia Smith · chair of the Compensation & People Committee · appointmenteff. 2023-06-13
- John Maraganore · Directors · departureeff. 2023-05-24
Latest filings
- 8-K · Company announcement2026-07-30
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-06-18
- 8-K · Company announcement2026-04-29
- 10-Q · Quarterly report2026-04-29
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AGIOS PHARMACEUTICALS, INC., every answer cited to the official filings🔒
- The Intelligence Brief — added when AGIOS PHARMACEUTICALS, INC.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.